Clinical Trials List
2022-01-19 - 2027-10-20
Phase III
Recruiting7
ICD-10I25.10
Atherosclerotic heart disease of native coronary artery without angina pectoris
ICD-9429.2
Cardiovascular disease, unspecified
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 李文煌 Division of Cardiovascular Diseases
- Ju-Yi Chen Division of Cardiovascular Diseases
- Po-Sheng Chen Division of Cardiovascular Diseases
- Yen-Wen Liu Division of Cardiovascular Diseases
- Po-Tseng Lee Division of Cardiovascular Diseases
- 陳柏偉 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yung-Ta Kao Division of Cardiovascular Diseases
- 蕭卜源 Division of Cardiovascular Diseases
- 陳志維 Division of Cardiovascular Diseases
- Chien-Yi Hsu Division of Cardiovascular Diseases
- 鄭宇倫 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林柏志 Division of General Internal Medicine
- 江君揚 Division of General Internal Medicine
- 陳盈憲 Division of General Internal Medicine
- JEN-KUANG LEE Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wen-Chung Yu Division of Cardiovascular Diseases
- 李慶威 Division of Cardiovascular Diseases
- Shih-Hsien Sung Division of Cardiovascular Diseases
- Chern-En Chiang Division of Cardiovascular Diseases
- Tse-Min Lu Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chun-Yuan Chu Division of Cardiovascular Diseases
- Ye-Hsu Lu Division of Cardiovascular Diseases
- 吳韋璁 Division of Cardiovascular Diseases
- Po-Chao Hsu Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
153 participants
-
Global
16500 participants
